Ultragenyx Pharmaceutical Inc.

RARE Healthcare Biotechnology

Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.1%, EPS grew 23.1% and free cash flow grew 12.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

14.54 0.63 −4.15%
Market cap
$1.5B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
5/9
Altman Z
−3.57
Beneish M
−2.68
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — 4 4 5 3 3 4 4 5
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
0.00 767.05 42.03 23.30 31.08 16.22 8.76 8.16 6.80 3.37
Altman Z-Score
22.93 6.91 8.85 0.89 7.35 3.73 (1.56) (2.05) (2.28) (3.57)
Altman Z″-Score (non-manufacturers)
5.33 (3.63) 1.72 (0.88) 1.86 (1.60) (5.73) (7.75) (8.70) (9.61)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(58.09) (25.57) (38.75) (33.54) (134.87) (104.91) (35.23) (42.10) (48.00) (22.72)
Beneish M-Score
— — 14.07 (0.53) (1.91) (2.38) (3.27) (2.08) (2.55) (2.68)
P/B ratio
5.84 5.46 3.55 3.70 7.30 6.18 9.03 12.86 14.93 0.00
Price to Tangible BV
5.84 10.59 4.97 5.03 8.60 7.63 21.51 54.69 115.37 0.00
EV/Sales
0.00 681.09 33.10 16.02 26.64 14.12 6.70 6.83 5.71 2.36
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(14.84) (7.32) (5.87) (4.81) (54.62) (14.65) (6.40) (6.24) (7.72) (3.41)
EV/FCF
(13.95) (7.24) (5.78) (4.49) (41.00) (12.05) (4.62) (5.68) (7.37) (3.26)
Quick Ratio
6.33 3.37 6.32 7.63 6.46 4.24 3.02 2.32 2.13 2.18
Current Ratio
6.67 3.80 6.99 8.24 6.83 4.72 3.38 2.61 2.38 2.48
Net Debt/EBITDA
1.59 0.73 1.30 1.79 3.79 2.05 1.19 1.04 1.19 1.35
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.01 0.09 0.11 0.19 0.21 0.24 0.29 0.37 0.44
Operating CF/Net income
0.65 0.84 1.47 0.86 0.71 0.75 0.54 0.78 0.73 0.81
Capex/Depreciation
(1.23) (0.37) (0.24) (10.68) (3.35) (3.68) (6.99) (3.62) (0.87) (0.68)
Interest Coverage
(65.45) (80.74) (38.92) (373.72) (9.92) (12.97) (15.09) (8.62) (8.51) (8.63)
ROE
(48.93%) (70.48%) (39.83%) (63.79%) (20.64%) (43.72%) (110.96%) (193.34%) (214.55%) (657.14%)
ROA
(44.70%) (58.59%) (32.65%) (43.42%) (12.89%) (27.67%) (46.12%) (39.98%) (38.01%) (37.89%)
ROIC
(167.73%) (138.02%) (155.57%) 0.00% 0.00% (130.83%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(68.59%) (137.08%) (42.25%) (50.85%) (15.82%) (55.61%) (80.17%) (81.77%) (77.00%) (70.90%)
Average Days of Receivables
0.00 722.73 90.30 115.59 31.10 29.53 40.63 61.72 79.52 85.69
Research and Development Expense of Revenue
137,747.37% 8,868.45% 570.93% 344.56% 152.04% 141.48% 194.26% 149.31% 124.64% 111.44%
Selling, General and Administrative Expense of Revenue
48,824.06% 3,825.00% 248.03% 155.74% 67.50% 62.60% 76.55% 71.43% 57.32% 51.86%
Intangible Assets out of Total Assets
0.00 0.38 0.24 0.15 0.10 0.12 0.13 0.14 0.15 0.14
Share Based Compensation of Revenue
36,322.56% 2,603.91% 155.56% 79.06% 31.63% 29.87% 35.88% 31.11% 28.21% 22.73%
Graham Net Nets
0.12 0.08 0.19 0.15 0.08 0.05 (0.10) (0.14) (0.11) (0.29)
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.33
Earnings Yield
(8.86%) (14.42%) (8.97%) (16.67%) (2.26%) (7.98%) (22.21%) (17.29%) (15.07%) (25.39%)
Free Cash Flow Yield
(6.18%) (12.26%) (13.61%) (15.32%) (2.09%) (7.22%) (16.55%) (14.74%) (11.40%) (21.47%)
Revenue per Share
0.00 0.06 1.03 1.83 4.45 5.18 5.20 5.90 6.19 6.83
Operating CF per Share
(4.07) (5.98) (5.84) (6.10) (2.17) (5.00) (5.44) (6.46) (4.57) (4.73)
Capex per Share
(0.26) (0.07) (0.08) (0.44) (0.72) (1.08) (2.09) (0.64) (0.22) (0.21)
Free Cash Flow per Share
(4.32) (6.05) (5.92) (6.54) (2.89) (6.07) (7.53) (7.10) (4.80) (4.94)
Cash per Share
9.64 5.52 9.24 13.35 19.75 10.92 10.70 7.85 6.74 6.90
Shareholders Equity per Share
11.97 9.03 12.23 11.56 18.97 13.61 5.04 3.75 2.82 (0.81)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
11.97 9.03 12.23 11.56 18.97 13.61 5.04 3.75 2.82 (0.81)
Free Cash Flow
(171.16) (256.64) (294.64) (370.21) (176.12) (411.79) (526.59) (522.00) (434.00) (487.00)
Working Capital
341.44 198.57 447.64 747.72 1,105.70 675.24 622.69 451.75 473.00 567.00
Capital Expenditures
(10.19) (2.79) (4.08) (24.83) (43.90) (73.09) (146.12) (47.00) (20.00) (21.00)
Net Current Asset Value
335.04 162.28 411.72 369.29 690.12 256.77 (309.05) (483.41) (431.00) (661.00)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
76.60 1.07 0.08 0.24 0.16 0.21 0.40 0.11 0.04 0.03
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.48 0.34 0.84 0.05 0.18 0.14 0.08 0.04 0.09 0.13
Cash ROIC
(20.01%) (41.53%) (27.57%) (26.28%) (7.48%) (24.77%) (47.86%) (61.22%) (50.17%) (81.17%)
Accounts Receivable Turnover
0.00 0.99 5.75 4.55 9.69 13.64 10.55 7.63 5.73 4.81
Accounts Payable Turnover
0.00 0.00 0.11 0.72 0.48 1.07 0.94 1.05 1.90 3.11
Inventory Turnover
— 0.00 0.29 0.97 0.50 1.09 1.32 1.48 1.95 2.25
Average Days of Payables
0.00 3,243,390.00 3,909.58 521.53 769.60 390.77 557.73 341.59 184.87 103.81
Days of Inventory on Hand
— 276,305.00 2,250.20 467.84 777.05 370.08 344.97 275.53 213.31 174.13
Average Receivables
— 2.64 8.96 22.79 27.97 25.76 34.44 56.92 97.70 140.00
Average Payables
4.15 7.13 10.58 12.57 12.90 15.03 30.21 42.69 40.56 35.00
Average Inventory
— 4.00 3.91 9.31 12.30 14.64 21.50 30.37 39.48 48.50
Average Assets
550.10 515.69 605.16 927.53 1,447.53 1,640.98 1,533.92 1,518.23 1,497.01 1,517.50
Average Common Equity
502.53 428.71 496.18 631.34 904.07 1,038.47 637.53 313.95 265.21 87.50

Fold the line items

Columns are period end dates